06.26.25 -- 25 Tips To Prepare A Clinical Site For FDA Inspection

The future of pharmaceutical access in Europe is being shaped by the new EU Health Technology Assessment (HTA) regulation. Discover insights from Pharma 2025 that shed light on this pivotal shift.

The FDA is embarking on a transformative initiative to phase out animal testing requirements.

Using QRM gives a company the ability to maintain compliance while also identifying product issues that could be harmful to the consumers, some being susceptible patients.

As biomarker-directed therapies drive advancements in the oncology space, experts are reviewing cutting-edge trends and strategies that help institutions address ethical and regulatory challenges.

For early-stage biotech companies, the road from discovery to market is fraught with challenges, and in this environment, strategic partnerships with CROs have become a cornerstone of clinical success.

Through careful planning, aligned incentives, and an open, adaptive mindset, master protocols become powerful engines for accelerating therapies to market—particularly in high-need therapeutic areas.

Uncover how we're able to bring integrated services and trusted scientific insight to every molecule and program.

Our approach is designed to optimize efficiency and accelerate timelines, resulting in up to 40% time savings throughout the early phases of your drug development journey.

We are manufacturing, packaging, and supply chain experts, harnessing experience and expertise to deliver you a seamless solution with the ultimate aim of improving the lives of patients.